Welcome to Arctom, sign up to enjoy up to 20% OFF
- Cart - 0 item(s)
- $0.00
Your shopping cart is empty!
- Chemistry
- Bioactive Molecules
- Anti-infection
- Apoptosis
- Autophagy
- Cell Cycle/DNA Damage
- Cytoskeleton
- Epigenetics
- GPCR/G Protein
- Immunology/Inflammation
- JAK/STAT Signaling
- MAPK/ERK Pathway
- Membrane Transporter/Ion Channel
- Metabolic Enzyme/Protease
- Neuronal Signaling
- NF-κB
- PI3K/Akt/mTOR
- PROTAC
- Protein Tyrosine Kinase/RTK
- Stem Cell/Wnt
- TGF-beta/Smad
- Vitamin D Related/Nuclear Receptor
- Others
- Methylation
- Cytoskeletal Signaling
- Natural Products
- Alkaloids
- Amino acid
- Anthraquinones
- Cerebrosides
- Chalcones
- Coumarins
- Diterpenoids
- Flavonoids
- Iridoids
- Lignans
- Lipids
- Miscellaneous
- Monoterpenoids
- Other terpenes
- Phenols
- Phenylpropanoids
- Quinones
- Saccharides
- Sesquiterpenoids
- Steroids
- Tetraterpenoids
- Thiophenes
- Triterpenoids
- Xanthones
- Polyphenols
- Stibene glucosides
- Oligose
- Anthocyanins
- Miscellaneous
- Chromones
- Terpenoids
- Indoles
- Procyanidins
- Aliphatics
- Botanical Cyclopeptides
- ADCs
- Antibodies
- Multiplex IHC
- Material Science
- Others
[CAS NO. 945721-28-8] Daratumumab
| Ships within | Stock | Price | Qty | Total |
Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.
| Catalog: | HY-P9915 |
| Brand: | MCE |
| CAS: | 945721-28-8 |
Overview
| MDL | - |
|---|---|
| Molecular Weight | - |
| Molecular Formula | - |
| SMILES | [Daratumumab] |
For research use only. We do not sell to patients.
Summary
Daratumumab (Anti-Human CD38) is the first-in-class human-specific anti-CD38 monoclonal antibody (IgG1). Daratumumab has anti-multiple myeloma (MM) effect. Daratumumab impairs MM cell adhesion, which results in an increased sensitivity of MM to proteasome inhibition [1] [2] .
In Vitro
Daratumumab (Anti-Human CD38) induces potent Ab-dependent cellular cytotoxicity in CD38-expressing lymphoma- and MM-derived cell lines [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Daratumumab (i.p.; 0.5 mg/kg; 14 d after challenge with Daudi-luc cells) inhibits outgrowth of CD38-expressing tumor cells in mouse xenograft tumor models [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | 8- to 10-wk-old C.B-17 SCID mice (luciferase-expressing Daudi cells) [2] |
| Dosage: | 0.5 mg/kg |
| Administration: | I.p.; 14 day after challenge with Daudi-luc cells |
| Result: | Effectively inhibited tumor growth compared with control-treated animals in which tumor grew rapidly and therefore required euthanasia on day 35. On day 28 and day 35, tumor size in Daratumumab-treated animals was significantly different from the control. |
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT03589222 | PETHEMA Foundation |
Refractory Multiple Myeloma
|
July 15, 2018 | Phase 2 |
| NCT03314181 | AbbVie|Janssen Research & Development, LLC |
Multiple Myeloma
|
April 2, 2018 | Phase 2 |
| NCT04756401 | Academic and Community Cancer Research United|National Cancer Institute (NCI) |
Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma
|
October 31, 2022 | Phase 2 |
| NCT03289299 | International Myeloma Foundation|Amgen|Janssen Scientific Affairs, LLC|Celgene|Trevie, Inc. |
Smoldering Multiple Myeloma
|
May 25, 2018 | Phase 2 |
| NCT01665794 | University of Chicago|National Cancer Institute (NCI)|Multiple Myeloma Research Foundation |
Multiple Myeloma
|
August 13, 2012 | Phase 1|Phase 2 |
| NCT05455320 | Janssen Research & Development, LLC |
Relapsed or Refractory Multiple Myeloma
|
October 13, 2022 | Phase 3 |
| NCT05434689 | University of Alabama at Birmingham |
Multiple Myeloma
|
December 2022 | Phase 1|Phase 2 |
| NCT03669445 | University Hospital, Toulouse |
Multiple Myeloma
|
December 31, 2018 | Phase 2 |
| NCT03989414 | Celgene |
Multiple Myeloma
|
September 30, 2019 | Phase 1|Phase 2 |
| NCT02060188 | Bristol-Myers Squibb |
Microsatellite Unstable Colorectal Cancer|Microsatellite Stable Colorectal Cancer|Mismatch Repair Proficient Colorectal Cancer|Mismatch Repair Deficient Colorectal Cancer
|
March 12, 2014 | Phase 2 |
| NCT03475628 | Hellenic Society of Hematology|Janssen Pharmaceuticals |
Multiple Myeloma
|
February 21, 2018 | Phase 2 |
| NCT04124497 | Fondazione EMN Italy Onlus |
Multiple Myeloma|Deletion 17P Syndrome
|
July 1, 2019 | Phase 2 |
| NCT03701321 | National Cancer Institute (NCI) |
Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma
|
January 25, 2019 | Phase 1|Phase 2 |
| NCT05259839 | TeneoOne Inc. |
Relapsed+Refractory Multiple Myeloma
|
October 20, 2022 | Phase 1 |
| NCT05280275 | Hellenic Society of Hematology|GlaxoSmithKline |
Multiple Myeloma|Neoplasms|Neoplasms, Plasma Cell|Gammopathy, Monoclonal|Paraproteinemias|Blood Protein Disorders|Haematologic Disease|Corneal Disease
|
March 15, 2022 | Phase 1|Phase 2 |
| NCT03217812 | Janssen Research & Development, LLC |
Multiple Myeloma
|
November 23, 2017 | Phase 3 |
| NCT04009109 | Alliance Foundation Trials, LLC.|Janssen Scientific Affairs, LLC|Celgene Corporation|Takeda |
Myeloma, Multiple
|
October 21, 2020 | Phase 2 |
| NCT04264884 | Janssen Research & Development, LLC |
|
||
| NCT02419118 | Vejle Hospital |
Multiple Myeloma
|
January 2015 | Phase 2|Phase 3 |
| NCT04975997 | Celgene |
Multiple Myeloma
|
June 23, 2022 | Phase 3 |
| NCT02413489 | Janssen Research & Development, LLC |
Lymphoma, Mantle-Cell|Lymphoma, Large B-Cell, Diffuse|Lymphoma, Follicular
|
September 2, 2015 | Phase 2 |
| NCT03201965 | Janssen Research & Development, LLC |
Amyloidosis
|
October 5, 2017 | Phase 3 |
| NCT05284591 | iOMEDICO AG |
Multiple Myeloma|Newly Diagnosed|Transplant Ineligible|Patient Satisfaction|Patient Preference|Personal Satisfaction
|
July 6, 2022 | |
| NCT03901963 | Janssen Research & Development, LLC |
Multiple Myeloma
|
April 26, 2019 | Phase 3 |
| NCT04722146 | Janssen Research & Development, LLC |
Multiple Myeloma
|
March 12, 2021 | Phase 1 |
| NCT05403138 | Tianjin Medical University General Hospital |
Neuromyelitis Optica|Neuromyelitis Optica Spectrum Disorder|NMO Spectrum Disorder
|
November 1, 2022 | Phase 2|Phase 3 |
| NCT05363111 | City of Hope Medical Center|National Cancer Institute (NCI) |
Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma
|
November 30, 2022 | Phase 1 |
| NCT03837509 | Incyte Corporation |
Relapsed or Refractory Multiple Myeloma
|
September 25, 2019 | Phase 1|Phase 2 |
| NCT03187262 | Dana-Farber Cancer Institute|Janssen, LP |
Waldenström Macroglobulinemia
|
November 27, 2017 | Phase 2 |
| NCT04113018 | Wake Forest University Health Sciences|Amgen|Celgene|Janssen, LP |
Multiple Myeloma
|
November 12, 2019 | Phase 2 |
| NCT03320707 | Janssen Research & Development, LLC |
Healthy
|
October 16, 2017 | Phase 1 |
| NCT04205240 | Srinivas Devarakonda|Ohio State University Comprehensive Cancer Center |
Recurrent Plasma Cell Myeloma
|
May 27, 2020 | Phase 2 |
| NCT04121260 | Janssen Research & Development, LLC |
Multiple Myeloma
|
December 25, 2019 | Phase 1 |
| NCT05451771 | Rajshekhar Chakraborty, MD|Genentech, Inc.|Columbia University |
AL Amyloidosis
|
October 26, 2022 | Phase 1|Phase 2 |
| NCT05289687 | Eastern Cooperative Oncology Group|Janssen, LP |
T-cell Acute Lymphoblastic Leukemia
|
June 16, 2022 | Phase 2 |
| NCT03207542 | M.D. Anderson Cancer Center|Janssen Scientific Affairs, LLC |
Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic
|
July 2018 | Phase 2 |
| NCT03697655 | Polish Myeloma Consortium|Janssen-Cilag Ltd.|Bioscience, S.A. |
Multiple Myeloma
|
December 10, 2018 | Phase 2 |
| NCT05497804 | Mayo Clinic|National Cancer Institute (NCI) |
ISS Stage III Plasma Cell Myeloma|Plasma Cell Myeloma
|
September 22, 2022 | Phase 2 |
| NCT05581875 | Hellenic Society of Hematology|GlaxoSmithKline |
Multiple Myeloma|Multiple Myeloma in Relapse|Neoplasms|Gammopathy, Monoclonal|Paraproteinemias|Blood Protein Disorders|Haematologic Disease|Corneal Disease|Neoplasms, Plasma Cell
|
October 20, 2022 | Phase 1|Phase 2 |
| NCT05088330 | The First Affiliated Hospital of Soochow University |
Newly Diagnosed Multiple Myeloma
|
December 1, 2021 | Not Applicable |
| NCT05408026 | Alliance Foundation Trials, LLC.|Janssen, LP|Celgene |
Relapsed or Refractory Multiple Myeloma
|
October 1, 2022 | Phase 1|Phase 2 |
| NCT03829371 | University of Turin, Italy |
Multiple Myeloma
|
January 3, 2019 | Phase 4 |
| NCT03412565 | Janssen Research & Development, LLC |
Multiple Myeloma
|
April 26, 2018 | Phase 2 |
| NCT03357952 | Janssen Research & Development, LLC |
Multiple Myeloma
|
November 16, 2017 | Phase 2|Phase 3 |
| NCT04827979 | National Institute of Allergy and Infectious Diseases (NIAID)|Immune Tolerance Network (ITN)|Bristol-Myers Squibb|PPD|Rho Federal Systems Division, Inc. |
Highly Sensitized Prospective Kidney Transplant Recipients
|
November 1, 2021 | Phase 1|Phase 2 |
| NCT04635189 | University of Rochester |
Multiple Myeloma
|
July 27, 2021 | Phase 2 |
| NCT04892446 | Gilead Sciences |
Multiple Myeloma
|
November 9, 2021 | Phase 2 |
| NCT02977494 | Universitätsklinikum Hamburg-Eppendorf |
Multiple Myeloma
|
June 2016 | Phase 2 |
| NCT04776018 | Takeda |
Relapsed and+or Refractory Multiple Myeloma (RRMM)
|
April 20, 2021 | Phase 1|Phase 2 |
| NCT02626481 | University Hospital, Lille|Janssen, LP|Intergroupe Francophone du Myelome |
Multiple Myeloma
|
December 28, 2015 | Phase 2 |
| NCT04270175 | Weill Medical College of Cornell University|Janssen Scientific Affairs, LLC |
Amyloid|AL Amyloidosis|Refractory AL Amyloidosis
|
April 14, 2021 | Phase 2 |
| NCT03537599 | Sumithira Vasu|Ohio State University Comprehensive Cancer Center |
Minimal Residual Disease|Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes|Recurrent Adult Acute Myeloid Leukemia|Recurrent Childhood Acute Myeloid Leukemia
|
January 10, 2020 | Phase 1|Phase 2 |
| NCT03622775 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Recurrent Plasma Cell Myeloma
|
April 11, 2019 | Phase 2 |
| NCT02477891 | Janssen Research & Development, LLC |
Multiple Myeloma
|
||
| NCT03283917 | M.D. Anderson Cancer Center|Janssen Pharmaceuticals|Takeda |
Newly Diagnosed Primary Amyloidosis|Recurrent Primary Amyloidosis|Refractory Primary Amyloidosis
|
February 7, 2018 | Phase 1 |
| NCT02541383 | Intergroupe Francophone du Myelome|HOVON - Dutch Haemato-Oncology Association|Janssen Research & Development, LLC |
Multiple Myeloma
|
September 2015 | Phase 3 |
| NCT03792620 | Grupo de Estudos Multicentricos em Onco-Hematologia |
Multiple Myeloma Stage I
|
November 20, 2018 | Phase 3 |
| NCT04895917 | IRCCS Policlinico S. Matteo |
AL Amyloidosis
|
June 23, 2021 | Phase 2 |
| NCT00574288 | Janssen Research & Development, LLC |
Multiple Myeloma
|
March 26, 2008 | Phase 2 |
| NCT05218603 | PETHEMA Foundation|Janssen, LP|Adknoma Health Research |
Multiple Myeloma|Non-eligible for Autologous Stem Cell Transplantation (ASCT)
|
November 30, 2021 | |
| NCT03606577 | Nantes University Hospital |
Multiple Myeloma
|
July 30, 2019 | Phase 2 |
| NCT02343042 | Karyopharm Therapeutics Inc |
Multiple Myeloma
|
October 2015 | Phase 1|Phase 2 |
| NCT04304144 | Caelum Biosciences, Inc.|Alexion Pharmaceuticals |
AL Amyloidosis
|
March 18, 2020 | Phase 2 |
| NCT02431208 | Hoffmann-La Roche |
Multiple Myeloma
|
July 22, 2015 | Phase 1 |
| NCT05137054 | Regeneron Pharmaceuticals |
Multiple Myeloma
|
August 17, 2022 | Phase 1 |
| NCT03896737 | European Myeloma Network|EMN Research Italy |
Multiple Myeloma
|
April 16, 2019 | Phase 2 |
| NCT02918331 | Janssen Pharmaceutical K.K. |
Multiple Myeloma
|
September 2016 | Phase 1 |
| NCT04288765 | Grupo Cooperativo de Hemopatías Malignas |
Multiple Myeloma
|
March 1, 2020 | Phase 3 |
| NCT04166565 | European Myeloma Network|Janssen, LP |
Multiple Myeloma|Extramedullary Plasmacytoma
|
October 31, 2019 | Phase 2 |
| NCT05004259 | Dartmouth-Hitchcock Medical Center |
Hemolytic Anemia
|
March 21, 2022 | Phase 1 |
| NCT03188172 | University of Leeds|Myeloma UK|Celgene|Janssen, LP |
Multiple Myeloma
|
September 28, 2017 | Phase 2 |
| NCT03290950 | Memorial Sloan Kettering Cancer Center|Janssen Pharmaceuticals |
Multiple Myeloma
|
September 25, 2017 | Phase 2 |
| NCT02316106 | Janssen Research & Development, LLC |
Multiple Myeloma
|
May 20, 2015 | Phase 2 |
| NCT04052880 | Ajai Chari|Janssen, LP|Icahn School of Medicine at Mount Sinai |
Newly Diagnosed Multiple Myeloma
|
October 24, 2019 | Phase 2 |
| NCT04925193 | University of Colorado, Denver|Karyopharm Therapeutics Inc|National Cancer Institute (NCI) |
Multiple Myeloma in Relapse
|
November 18, 2021 | Phase 2 |
| NCT03993912 | University Hospital, Lille |
Multiple Myeloma
|
October 17, 2019 | Phase 3 |
| NCT05205252 | Epizyme, Inc. |
Relapsed+Refractory
|
December 22, 2021 | Phase 1|Phase 2 |
| NCT04703621 | Ostfold Hospital Trust|Haukeland University Hospital|Oslo University Hospital|University Hospital, Akershus|Henri Mondor University Hospital|Odense University Hospital |
ITP
|
January 21, 2021 | Phase 2 |
| NCT03004287 | University of Arkansas|Janssen, LP |
Multiple Myeloma
|
July 1, 2017 | Phase 2 |
| NCT03035357 | M.D. Anderson Cancer Center|Janssen-Cilag div. of Johnson&Johnson SE |
Malignant Neoplasms of Male Genital Organs|Prostate Cancer
|
March 1, 2017 | Phase 2 |
| NCT03067571 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
High Risk Myelodysplastic Syndrome|Recurrent Acute Myeloid Leukemia|Refractory Acute Myeloid Leukemia
|
October 27, 2017 | Phase 2 |
| NCT03742297 | PETHEMA Foundation |
Newly Diagnosed Multiple Myeloma
|
October 22, 2018 | Phase 3 |
| NCT03221634 | Merck Sharp & Dohme LLC |
Multiple Myeloma
|
August 1, 2017 | Phase 2 |
| NCT04566328 | ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group |
Plasma Cell Myeloma|RISS Stage I Plasma Cell Myeloma|RISS Stage II Plasma Cell Myeloma
|
October 27, 2020 | Phase 3 |
| NCT05561049 | The First Affiliated Hospital of Soochow University |
Newly Diagnosed Multiple Myeloma
|
October 1, 2022 | |
| NCT03095118 | Fernando Fervenza|Mayo Clinic |
Membranoproliferative Glomerulonephritis
|
September 7, 2017 | Phase 2 |
| NCT03158688 | Amgen |
Relapsed Multiple Myeloma|Refractory Multiple Myeloma
|
June 13, 2017 | Phase 3 |
| NCT03490344 | Memorial Sloan Kettering Cancer Center|Janssen Scientific Affairs, LLC |
Multiple Myeloma
|
May 3, 2018 | Phase 2 |
| NCT03481556 | Oncopeptides AB |
Multiple Myeloma
|
April 16, 2018 | Phase 1|Phase 2 |
| NCT03556332 | Memorial Sloan Kettering Cancer Center|Janssen Pharmaceuticals |
Multiple Myeloma
|
July 2, 2018 | Phase 2 |
| NCT03432741 | Mayo Clinic|National Cancer Institute (NCI) |
Breast Adenocarcinoma|Metastatic Breast Carcinoma|Recurrent Breast Carcinoma|Recurrent Hodgkin Lymphoma|Recurrent Mycosis Fungoides|Recurrent Non-Hodgkin Lymphoma|Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Refractory Breast Carcinoma|Refractory Hodgkin Lymphoma|Refractory Mycosis Fungoides|Refractory Nodal Marginal Zone Lymphoma|Refractory Non-Hodgkin Lymphoma|Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Stage IV Breast Cancer AJCC v6 and v7
|
March 27, 2018 | Phase 1 |
| NCT03500445 | University of Chicago|Janssen Scientific Affairs, LLC|Amgen |
Myeloma|Multiple Myeloma
|
February 13, 2019 | Phase 2 |
| NCT04065789 | Tel-Aviv Sourasky Medical Center |
Myeloma Multiple|Myeloma, Plasma-Cell|Myeloma-Multiple|Plasma Cell Myeloma
|
May 2, 2018 | Phase 2 |
| NCT03439293 | Takeda |
Multiple Myeloma
|
March 13, 2018 | Phase 2 |
| NCT04933539 | National Cancer Institute (NCI)|Janssen Scientific Affairs, LLC|National Institutes of Health Clinical Center (CC) |
Multiple Myeloma
|
October 31, 2022 | Phase 2 |
| NCT04972942 | New York Medical College |
T-cell Acute Lymphoblastic Leukemia|T-Cell Acute Lymphoblastic Lymphoma
|
September 2021 | Phase 2 |
| NCT02807558 | Syros Pharmaceuticals |
Acute Myeloid Leukemia|Myelodysplastic Syndrome
|
August 2016 | Phase 2 |
| NCT03679624 | Weill Medical College of Cornell University|Janssen Scientific Affairs, LLC|Mayo Clinic |
Waldenstrom Macroglobulinemia|Waldenstrom´s Disease|Waldenström; Hypergammaglobulinemia|Waldenstrom´s Macroglobulinemia Recurrent|Waldenstrom´s Macroglobulinemia of Lymph Nodes|Waldenstrom´s Macroglobulinaemia, Without Mention of Remission|Waldenstrom´s Macroglobulinemia Refractory
|
July 30, 2020 | Phase 2 |
| NCT02116569 | Janssen Pharmaceutical K.K. |
Multiple Myeloma
|
April 2014 | Phase 1 |
| NCT04667663 | Cancer Trials Ireland|Janssen Pharmaceuticals|Celgene |
Multiple Myeloma
|
November 2021 | Phase 1 |
| NCT02944565 | Ohio State University Comprehensive Cancer Center |
Plasma Cell Myeloma
|
February 22, 2017 | Phase 2 |
| NCT04176718 | Andrew Yee, MD|Amgen|Janssen Research & Development, LLC|Massachusetts General Hospital |
Multiple Myeloma|Refractory Multiple Myeloma|Multiple Myeloma in Relapse|Relapse
|
May 18, 2020 | Phase 2 |
| NCT01998971 | Janssen Research & Development, LLC |
Multiple Myeloma
|
February 18, 2014 | Phase 1 |
| NCT05623020 | Pfizer |
Multiple Myeloma
|
November 15, 2022 | Phase 3 |
| NCT04223661 | Tyler Davis, MD, FACP|Janssen Scientific Affairs, LLC|Indiana Institute for Medical Research|Indiana University |
Multiple Myeloma
|
December 6, 2021 | Phase 2 |
| NCT02773030 | Celgene |
Multiple Myeloma
|
October 14, 2016 | Phase 1|Phase 2 |
| NCT05243342 | Genentech, Inc. |
Multiple Myeloma
|
April 28, 2022 | Phase 1 |
| NCT04131309 | European Myeloma Network|Janssen Pharmaceutica |
Light Chain (AL) Amyloidosis, Stage 3B
|
September 23, 2019 | Phase 2 |
| NCT04782687 | US Oncology Research|Karyopharm Therapeutics Inc |
Multiple Myeloma|Myeloma Multiple|Kahler Disease|Myeloma, Plasma Cell|Myeloma-Multiple|Myelomatosis|Plasma Cell Myeloma
|
September 10, 2021 | Phase 2 |
| NCT04810754 | Charite University, Berlin, Germany|Janssen-Cilag G.m.b.H|Labor Berlin-Charité Vivantes G.m.b.H|Deutsches Rheuma-Forschungszentrum Berlin (DRFZ)|Charité Clinical Trial Office (CTO) |
Systemic Lupus Erythematosus
|
June 30, 2021 | Phase 2 |
| NCT05250973 | Janssen Research & Development, LLC |
Amyloidosis
|
March 1, 2022 | Phase 2 |
| NCT04251065 | Fondazione Italiana Linfomi ONLUS |
Refractory T-Cell Lymphoma|Relapsed T-Cell Lymphoma
|
September 3, 2020 | Phase 2 |
| NCT03180736 | European Myeloma Network|Janssen Research & Development, LLC |
Multiple Myeloma
|
June 12, 2017 | Phase 3 |
| NCT03068351 | Hoffmann-La Roche |
Multiple Myeloma
|
June 26, 2017 | Phase 1 |
| NCT04302324 | Weill Medical College of Cornell University|Janssen Scientific Affairs, LLC |
Multiple Myeloma|Refractory Multiple Myeloma|Relapse Multiple Myeloma
|
October 28, 2021 | Phase 2 |
| NCT01415882 | Mayo Clinic|National Cancer Institute (NCI) |
Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma
|
January 31, 2012 | Phase 2 |
| NCT02488759 | Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd |
Various Advanced Cancer
|
October 13, 2015 | Phase 1|Phase 2 |
| NCT03734198 | French Innovative Leukemia Organisation|Janssen, LP |
Relapsed or Refractory Chronic Lymphocytic Leukemia
|
December 19, 2018 | Phase 2 |
| NCT02807454 | Celgene |
Multiple Myeloma
|
July 7, 2016 | Phase 2 |
| NCT04133636 | Janssen Research & Development, LLC |
Multiple Myeloma
|
November 7, 2019 | Phase 2 |
| NCT03757221 | University Hospital, Caen |
Multiple Myeloma
|
February 7, 2019 | Phase 2 |
| NCT05020236 | Pfizer |
Multiple Myeloma
|
October 4, 2021 | Phase 3 |
| NCT03236428 | Dana-Farber Cancer Institute|Janssen Pharmaceuticals|Multiple Myeloma Research Consortium|Blood Cancer Research Partnership|The Leukemia and Lymphoma Society |
Monoclonal Gammopathy|Smoldering Multiple Myeloma
|
November 24, 2017 | Phase 2 |
| NCT04088903 | Ronald Witteles|Stanford University |
Allosensitization|Heart Transplant Failure and Rejection
|
April 1, 2021 | Phase 1 |
| NCT02252172 | Janssen Research & Development, LLC |
Multiple Myeloma
|
February 16, 2015 | Phase 3 |
| NCT04892264 | Mayo Clinic|National Cancer Institute (NCI) |
Plasma Cell Myeloma|Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma
|
June 4, 2021 | Phase 1|Phase 2 |
| NCT04661137 | Hackensack Meridian Health|Karyopharm Therapeutics Inc |
Multiple Myeloma
|
March 16, 2021 | Phase 2 |
| NCT04139304 | AIDS Malignancy Consortium|National Cancer Institute (NCI)|Janssen Scientific Affairs, LLC|Montefiore Medical Center|Memorial Sloan Kettering Cancer Center|AIDS and Cancer Specimen Resource|The Emmes Company, LLC |
Plasmablastic Lymphoma|Ann Arbor Stage I Diffuse Large B-Cell Lymphoma|Ann Arbor Stage II Diffuse Large B-Cell Lymphoma|Ann Arbor Stage III Diffuse Large B-Cell Lymphoma|Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma
|
May 24, 2021 | Early Phase 1 |
| NCT02497378 | Janssen Pharmaceutical K.K. |
Multiple Myeloma
|
July 10, 2015 | Phase 1 |
| NCT05556616 | Takeda |
Multiple Myeloma
|
October 27, 2022 | Phase 1 |
| NCT04915248 | Fondazione Italiana Linfomi ONLUS|Janssen-Cilag S.p.A. |
Plasmablastic Lymphoma
|
July 11, 2022 | Phase 2 |
| NCT04181827 | Janssen Research & Development, LLC |
Multiple Myeloma
|
June 12, 2020 | Phase 3 |
| NCT04230031 | Wake Forest University Health Sciences|Janssen Research & Development, LLC |
Multiple Myeloma
|
July 2, 2021 | Phase 2 |
| NCT04280328 | Corvus Pharmaceuticals, Inc. |
Multiple Myeloma
|
February 20, 2020 | Phase 1 |
| NCT01985126 | Janssen Research & Development, LLC |
Multiple Myeloma
|
September 27, 2013 | Phase 2 |
| NCT04396496 | University of Arkansas|Janssen Scientific Affairs, LLC |
POEMS Syndrome
|
September 22, 2020 | Phase 2 |
| NCT05392946 | Mayo Clinic|National Cancer Institute (NCI) |
Plasma Cell Myeloma
|
August 11, 2022 | Phase 1|Phase 2 |
| NCT04140162 | University of Michigan Rogel Cancer Center|Janssen Scientific Affairs, LLC |
Multiple Myeloma
|
October 5, 2020 | Phase 2 |
| NCT02927925 | Janssen Research & Development, LLC |
Lymphoma
|
February 14, 2017 | Phase 2 |
| NCT04649060 | Oncopeptides AB |
Relapse Multiple Myeloma|Multiple Myeloma
|
December 7, 2020 | Phase 3 |
| NCT03942224 | Emory University|Takeda|Janssen, LP |
Plasma Cell Myeloma
|
July 3, 2019 | Phase 2 |
| NCT04151667 | H. Lee Moffitt Cancer Center and Research Institute|Janssen Scientific Affairs, LLC |
Multiple Myeloma
|
November 22, 2019 | Phase 2 |
| NCT05300451 | Barry A. Boilson|Janssen Biotech, Inc.|Mayo Clinic |
Antibody-mediated Rejection|Cardiac Transplant
|
March 31, 2022 | Phase 2 |
| NCT02951819 | Janssen Scientific Affairs, LLC |
Multiple Myeloma
|
November 9, 2016 | Phase 2 |
| NCT03450057 | Hellenic Society of Hematology|Janssen Pharmaceuticals |
Multiple Myeloma
|
February 15, 2018 | Phase 2 |
| NCT03000452 | Celgene |
Multiple Myeloma
|
March 14, 2017 | Phase 2 |
| NCT04246047 | GlaxoSmithKline |
Multiple Myeloma
|
May 7, 2020 | Phase 3 |
| NCT04922723 | West Virginia University |
Glioblastoma
|
October 2022 | Phase 1|Phase 2 |
| NCT04352205 | Emory University|Janssen Scientific Affairs, LLC|National Cancer Institute (NCI) |
Plasma Cell Myeloma|Renal Failure
|
May 7, 2020 | Phase 2 |
| NCT04230304 | Mayo Clinic|National Cancer Institute (NCI) |
Recurrent Chronic Lymphocytic Leukemia|Recurrent Chronic Lymphocytic Leukemia+Small Lymphocytic Lymphoma|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Small Lymphocytic Lymphoma
|
September 16, 2020 | Phase 2 |
| NCT04136756 | Nektar Therapeutics |
Multiple Myeloma|Non-Hodgkin Lymphoma|Indolent Non-Hodgkin Lymphoma
|
October 7, 2019 | Phase 1 |
| NCT03841565 | Academic and Community Cancer Research United|Janssen Scientific Affairs, LLC|National Cancer Institute (NCI) |
Recurrent Plasma Cell Myeloma
|
August 7, 2020 | Phase 2 |
| NCT04474938 | Peking Union Medical College Hospital|Xian-Janssen Pharmaceutical Ltd. |
Amyloidosis; Systemic
|
May 24, 2021 | Phase 2 |
| NCT02195479 | Janssen Research & Development, LLC |
Multiple Myeloma
|
December 9, 2014 | Phase 3 |
| NCT03937635 | ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group |
Smoldering Plasma Cell Myeloma
|
April 30, 2019 | Phase 3 |
| NCT04407442 | University of California, San Francisco|Janssen Pharmaceuticals|Multiple Myeloma Research Foundation |
Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma
|
November 30, 2020 | Phase 2 |
| NCT05552222 | Janssen Research & Development, LLC |
Multiple Myeloma
|
October 25, 2022 | Phase 3 |
| NCT04614636 | Fate Therapeutics |
Acute Myeloid Leukemia|AML, Adult|Multiple Myeloma|Myeloma
|
October 17, 2020 | Phase 1 |
| NCT05486481 | Sandy Wong, MD|Janssen Pharmaceuticals|AbbVie|University of California, San Francisco |
AL Amyloidosis|Light Chain (AL) Amyloidosis|Systemic Light Chain Disease
|
January 15, 2023 | Phase 1|Phase 2 |
| NCT04656951 | University of Cologne|Janssen-Cilag G.m.b.H |
Multiple Myeloma
|
June 1, 2021 | Phase 2 |
| NCT02519452 | Janssen Research & Development, LLC |
Multiple Myeloma
|
October 22, 2015 | Phase 1 |
| NCT04868838 | Mayo Clinic |
Lupus Nephritis
|
April 20, 2021 | Phase 2 |
| NCT05083169 | Janssen Research & Development, LLC |
Multiple Myeloma
|
October 14, 2021 | Phase 3 |
| NCT02874742 | Janssen Research & Development, LLC |
Multiple Myeloma
|
August 29, 2016 | Phase 2 |
| NCT03384654 | Janssen Research & Development, LLC |
Precursor Cell Lymphoblastic Leukemia-Lymphoma
|
May 14, 2018 | Phase 2 |
| NCT03695744 | Singapore General Hospital|International Myeloma Foundation|Janssen, LP |
Multiple Myeloma|Myeloma
|
October 2, 2019 | Phase 2 |
| NCT03992170 | Azienda Ospedaliera Universitaria Senese|Janssen-Cilag S.p.A. |
Myeloma Multiple
|
December 31, 2018 | Phase 2 |
| NCT05561387 | Southwest Oncology Group|National Cancer Institute (NCI) |
Plasma Cell Myeloma
|
December 1, 2022 | Phase 3 |
| NCT01592370 | Bristol-Myers Squibb|Janssen, LP |
Non-Hodgkin´s Lymphoma|Hodgkin Lymphoma|Multiple Myeloma
|
August 2, 2012 | Phase 1|Phase 2 |
| NCT04513639 | Oslo University Hospital|St. Olavs Hospital|Haukeland University Hospital|University Hospital of North Norway|University Hospital, Akershus|Helse Stavanger HF|Førde Central Hospital|Sorlandet Hospital HF|Nordlandssykehuset HF|The Hospital of Vestfold|Helse Nord-Trøndelag HF|Alesund Hospital|Sykehuset Ostfold |
Multiple Myeloma
|
August 27, 2020 | Phase 2|Phase 3 |
| NCT04910568 | Genentech, Inc.|Hoffmann-La Roche |
Multiple Myeloma
|
July 26, 2021 | Phase 1 |
| NCT05145296 | University Hospital, Grenoble|Bristol-Myers Squibb |
Sensitisation|Highly Sensitised Dialysis Patients
|
January 19, 2022 | Not Applicable |
| NCT05139225 | Memorial Sloan Kettering Cancer Center|Trillium Therapeutics Inc. |
Multiple Myeloma
|
October 28, 2021 | Phase 1 |
| NCT05054478 | Assistance Publique - Hôpitaux de Paris |
Plasma Cell Leukemia
|
October 2021 | Phase 2 |
| NCT03477539 | Mayo Clinic|National Cancer Institute (NCI) |
Plasma Cell Myeloma
|
April 9, 2018 | Phase 2 |
| NCT03710603 | European Myeloma Network|Janssen Research & Development, LLC |
Multiple Myeloma
|
December 14, 2018 | Phase 3 |
| NCT03301220 | Janssen Research & Development, LLC |
Smoldering Multiple Myeloma
|
November 7, 2017 | Phase 3 |
| NCT05562882 | Institute of Hematology & Blood Diseases Hospital |
Immune Thrombocytopenia
|
October 15, 2022 | Early Phase 1 |
| NCT02852837 | Janssen Research & Development, LLC |
Multiple Myeloma
|
September 26, 2016 | Phase 1 |
| NCT05572229 | University Hospital, Lille |
Multiple Myeloma
|
February 2023 | Phase 2 |
| NCT03697629 | Canadian Myeloma Research Group |
Multiple Myeloma in Relapse
|
December 3, 2018 | Phase 2 |
| NCT04956302 | Abdullah Khan|Ohio State University Comprehensive Cancer Center |
Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma
|
September 27, 2021 | Phase 1 |
| NCT03311828 | City of Hope Medical Center |
Recurrent Plasma Cell Myeloma|Plasma Cell Myeloma|Secondary Amyloidosis
|
February 21, 2018 | Phase 1 |
| NCT04204980 | Assistance Publique - Hôpitaux de Paris|Janssen, LP |
Allosensitization|Kidney Transplant Rejection|Antibody-mediated Rejection
|
February 18, 2020 | Phase 1|Phase 2 |
| NCT05182073 | Fate Therapeutics |
Multiple Myeloma|Myeloma
|
November 24, 2021 | Phase 1 |
| NCT02841033 | Boston Medical Center|Janssen Pharmaceuticals |
AL Amyloidosis
|
March 20, 2017 | Phase 1|Phase 2 |
| NCT03768960 | Johnson & Johnson Private Limited |
Multiple Myeloma
|
June 10, 2019 | Phase 4 |
| NCT03012880 | Mayo Clinic|National Cancer Institute (NCI) |
Plasma Cell Myeloma
|
April 12, 2017 | Phase 2 |
| NCT04895410 | AbbVie |
Multiple Myeloma
|
January 17, 2022 | Phase 1 |
| NCT05050097 | Janssen Research & Development, LLC |
Multiple Myeloma
|
September 22, 2021 | Phase 1 |
| NCT03652064 | Janssen Research & Development, LLC |
Multiple Myeloma
|
November 6, 2018 | Phase 3 |
| NCT03098550 | Bristol-Myers Squibb|Janssen Biotech, Inc. |
Advanced Cancer
|
June 15, 2017 | Phase 1|Phase 2 |
| NCT01615029 | Janssen Research & Development, LLC |
Multiple Myeloma
|
June 26, 2012 | Phase 1|Phase 2 |
| NCT03234972 | Janssen Research & Development, LLC |
Multiple Myeloma
|
November 30, 2017 | Phase 3 |
| NCT04775550 | Omar Nadeem|Janssen, LP|Dana-Farber Cancer Institute |
High-risk Smoldering Multiple Myeloma|Multiple Myeloma
|
April 9, 2021 | Phase 2 |
| NCT04070378 | Marc L Gordon, MD|Janssen Scientific Affairs, LLC|Northwell Health |
Alzheimer Disease
|
November 6, 2019 | Phase 2 |
| NCT02136134 | Janssen Research & Development, LLC |
Multiple Myeloma
|
August 15, 2014 | Phase 3 |
| NCT05590377 | Takeda |
Multiple Myeloma
|
December 15, 2022 | Phase 1|Phase 2 |
| NCT04108195 | Janssen Research & Development, LLC |
Multiple Myeloma
|
February 21, 2020 | Phase 1 |
| NCT05527340 | PETHEMA Foundation|Celgene-BMS|Janssen-Cilag, S.A.|LIDESEC |
Multiple Myeloma
|
September 2022 | Phase 2 |
| NCT03011034 | Janssen Research & Development, LLC |
Myelodysplastic Syndromes
|
February 14, 2017 | Phase 2 |
| NCT03651128 | Celgene |
Multiple Myeloma
|
April 16, 2019 | Phase 3 |
| NCT02816476 | University Hospital, Limoges |
Amyloidosis
|
September 2016 | Phase 2 |
| NCT03763162 | M.D. Anderson Cancer Center|Takeda |
Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma
|
January 17, 2019 | Phase 2 |
| NCT03591744 | City of Hope Medical Center|National Cancer Institute (NCI) |
Plasma Cell Leukemia
|
October 25, 2018 | Phase 1 |
| NCT05257083 | European Myeloma Network|Janssen Research & Development, LLC |
Multiple Myeloma
|
December 2022 | Phase 3 |
| NCT01946477 | Celgene |
Multiple Myeloma
|
May 29, 2014 | Phase 2 |
| NCT04268498 | University of Miami|Amgen|Janssen Pharmaceuticals |
Multiple Myeloma
|
February 11, 2020 | Phase 2 |
| NCT03023423 | Janssen Research & Development, LLC|Genentech, Inc. |
Carcinoma, Non-Small-Cell Lung
|
December 23, 2016 | Phase 1|Phase 2 |
| NCT03346135 | City of Hope Medical Center|National Cancer Institute (NCI) |
Plasma Cell Myeloma|Secondary Amyloidosis
|
July 17, 2019 | Phase 2 |
| NCT05511428 | Thomas Jefferson University|Janssen Scientific Affairs, LLC |
Plasma Cell Myeloma
|
December 2022 | Not Applicable |
| NCT03473730 | M.D. Anderson Cancer Center|Janssen Research & Development, LLC|National Cancer Institute (NCI) |
Bladder Urothelial Carcinoma|Clear Cell Renal Cell Carcinoma|Malignant Urinary System Neoplasm|Metastatic Kidney Carcinoma|Stage IV Renal Cell Cancer AJCC v8
|
May 29, 2018 | Early Phase 1 |
| NCT05438043 | Janssen Research & Development, LLC |
Multiple Myeloma
|
December 23, 2022 | Phase 3 |
| NCT03447808 | Jennifer Woyach|Ohio State University Comprehensive Cancer Center |
Chronic Lymphocytic Leukemia
|
August 16, 2018 | Phase 1 |
| NCT03177460 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Prostate Adenocarcinoma|Stage III Prostate Cancer AJCC v8|Stage IIIA Prostate Cancer AJCC v8|Stage IIIB Prostate Cancer AJCC v8|Stage IIIC Prostate Cancer AJCC v8|Testosterone Greater Than 150 ng+dL
|
June 7, 2017 | Phase 1 |
| NCT04497961 | Memorial Sloan Kettering Cancer Center|Janssen Scientific Affairs, LLC |
Multiple Myeloma
|
August 28, 2020 | Phase 2 |
| NCT02076009 | Janssen Research & Development, LLC |
Multiple Myeloma
|
May 23, 2014 | Phase 3 |
| NCT02955810 | National University of Ireland, Galway, Ireland|Janssen Pharmaceuticals|Cancer Trials Ireland |
Multiple Myeloma
|
November 2016 | Phase 1 |
| NCT04586426 | Janssen Research & Development, LLC |
Multiple Myeloma
|
December 15, 2020 | Phase 1 |
| NCT04024384 | Assistance Publique - Hôpitaux de Paris |
Multiple Myeloma
|
July 2019 | Phase 2 |
| NCT04700176 | Hackensack Meridian Health|Janssen, LP |
Multiple Myeloma
|
May 2, 2022 | Phase 2 |
Appearance
Liquid
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
References
- [1] Ghose J, Viola D, et al. Daratumumab induces CD38 internalization and impairs myeloma cell adhesion. Oncoimmunology. 2018;7(10):e1486948. Published 2018 Jul 23.
- [2] de Weers M, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol. 2011;186(3):1840-1848.
Request a Quote
Please fill in your details below to request a COA for our product. We will send the COA to the provided email address promptly.
Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.
Information
Customer service
My account
Powered by Arctom
Copyright © 2021 Arctom. All rights reserved.